ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
Egrifta (tesamorelin) - Commercial
Prior Authorization, Quantity Limit
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါစဲးပတ့ဘၢၣ် 01, 2024
လံာ်တီလံာ်မီတဖၣ်ဒီး လံာ်ကွီၣ်ဒိတဖၣ်အစၢတဖၣ်
တၢ်ပာ်ဖျါ 1701 - 1710 လၢ 3470 အစၢတဖၣ်အကျါ
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP68-24 MHCP Pharmacy Benefit Exclusion for Kisunla™, PiaSky®, and Tecelra®
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါအီကူာ် 28, 2024
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP67-24 Commercial Pharmacy Benefit Exclusion for edaravone, Kisunla™, PiaSky®, and Tecelra®
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါအီကူာ် 28, 2024
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP65-24 PCA Agency Requirements
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါအီကူာ် 28, 2024
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP66-24 Reminder: Patient Complaint Policy and Process Requirements
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါအီကူာ် 28, 2024
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP62-24 Commercial Pharmacy Benefit Update: New and Revised Drug-Related Prior Authorization (PA) Requirement Notification, Effective October 1, 2024
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါအီကူာ် 14, 2024
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP64-24 MHCP Pharmacy Benefit Exclusion for Rytelo™
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါအီကူာ် 14, 2024
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP63-24 MHCP Pharmacy Benefit Update: Revised Drug-Related Prior Authorization (PA) Requirement Notification, Effective September 1, 2024
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါအီကူာ် 14, 2024
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P49-24 eviCore Healthcare Specialty Utilization Management (UM) Program: Radiation Oncology Clinical Guideline Updates
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါအီကူာ် 01, 2024
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P50-24 New Medical, Medical Drug and Behavioral Health Policy Management Updates, Effective October 7, 2024
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါအီကူာ် 01, 2024